On Friday, Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $26.03 which represents a decrease of $-0.12 or -0.46% from the prior close of $26.15. The stock opened at $26.15 ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

Sarepta Therapeutics今日宣布与Arrowhead ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its target price trimmed by Sanford C. Bernstein from $27.00 to $24 ...

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Arrowhead Pharmaceuticals, Inc. (ARWR) has disclosed a new risk, in the Sales & Marketing category. The reliance of Arrowhead ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its price target trimmed by Citigroup from $27.00 to $26.00 in a ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

11月26日宣布的Sarepta与Arrowhead Pharmaceuticals (NASDAQ:ARWR)的最新合作关系重新引发了投资者的浓厚兴趣。消息公布后，Sarepta股价在收盘时上涨了14%。这笔交易被视为一个积极举措，解决了人们对近期催化剂和长期可持续增长的担忧。

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

Sarepta Therapeutics今天早些时候披露了与Arrowhead的新合作关系，收购了四个临床阶段的管线项目，涵盖神经肌肉、肺部和中枢神经系统（CNS）疾病等多个治疗领域。此外，该交易还包括三个临床前CNS项目和六个发现阶段项目。